Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044031
Status:
COMPLETED
Last Update Posted:
2014-04-17
First Post:
2002-08-16
Brief Title:
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Sponsor:
Cancer Advances Inc
Organization:
Cancer Advances Inc
Study Overview
Official Title:
Prospective Randomized Controlled Double-Blind Multi-National Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced Nonresectable Stage II and III Recurrent Disease Following Primary Resection or Metastatic Stage IV Adenocarcinoma of the Pancreas Protocol No PC4
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test whether the G17DT Immunogen when administered in combination with chemotherapy is an effective and safe treatment for pancreatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None